Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Avant Diagnostics, Inc. (AVDX) Starts Presentation at SeeThruEquity Conference

Avant Diagnostics (OTC: AVDX) is a medical diagnostic technology company that specializes in large panel biomarker tests. Its first test, OvaDx®, is proposed for use in monitoring women previously diagnosed with ovarian cancer. OvaDx® is a sophisticated microarray-based test that measures the activation of the immune system in blood samples in response to ovarian tumor cell development. Pre-clinical research studies with OvaDx® indicate high sensitivity and specificity for all types and stages of ovarian cancer. Avant intends to sell or license OvaDx® and to expand its portfolio of diagnostic tests in the future. For more information, visit the company’s website at

The 5th Annual SeeThruEquity conference, held in New York City, will connect more than 50 presenting companies with microcap-focused investors, sponsors, and industry professionals in attendance. The conference will feature 30-minute presentations by presenting companies, as well as one-on-one meetings with investors. In addition to the large number of companies confirmed to present, SeeThruEquity is hosting a panel composed of industry leaders. For more information on SeeThruEquity, visit
This entry was posted in SeeThruEquity Conference. Bookmark the permalink.

Comments are closed.